查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830988

荷爾蒙替代療法市場

Hormone Replacement Therapy Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

荷爾蒙替代療法市場預測為利害關係人提供了製定成長策略的洞見。預計該市場規模將從2024年的98.5億美元增加至2031年的148.2億美元，2025年至2031年的複合年成長率（CAGR）預計為7.3%。受荷爾蒙失調發病率上升、人們對荷爾蒙缺乏症認知的提高以及HRT配方的進步等因素的影響，全球對荷爾蒙替代療法 (HRT) 的需求持續成長。生物同質性荷爾蒙替代療法 (BHRT) 因其公認的安全性和有效性，正逐漸取代合成荷爾蒙。 BHRT源自天然，被認為能夠與人體產生的荷爾蒙高度相似。

製藥公司正致力於研發創新的荷爾蒙療法配方，包括透皮貼片、凝膠、乳霜和皮下植入劑，以提高患者的便利性、依從性和安全性。這一趨勢正在推動荷爾蒙替代療法市場的成長。 2023年8月，美國食品藥物管理局 (FDA) 批准了ANI Pharmaceuticals公司0.1%雌二醇凝膠的簡化新藥申請。參考藥物Divigel是一種雌激素療法，用於緩解與更年期相關的中度至重度血管舒縮症狀。 Divigel的學名藥為0.1%雌二醇凝膠。

成長動力：廣泛的應用推動荷爾蒙替代療法市場成長。荷爾蒙替代療法用於緩解更年期症狀、治療生長激素缺乏症等，顯著影響著人們的生活。數百萬女性使用荷爾蒙替代療法 (HRT)，且通常持續較長時間。 HRT 有助於預防骨質疏鬆症，並透過多種方式提高生活品質。根據俄勒岡健康與科學大學的數據，生長激素缺乏症 (GHD) 相對罕見，在美國約有 5 萬名成年人和約 4,000 至 6,000 名兒童患有此病。因此，隨著荷爾蒙紊亂盛行率的上升，荷爾蒙替代療法的普及率不斷提高，推動了荷爾蒙替代療法市場的成長。

限制因素：高昂的藥物成本阻礙荷爾蒙替代療法市場的成長。 HRT 產品的價格尤其高昂。例如，根據更年期中心的報告，口服荷爾蒙替代療法處方的每月費用在 130 美元至 240 美元之間（相當於每年 1,560 美元至 2,440 美元）。這些高昂的費用阻礙了這些產品的常規使用，從而抑制了荷爾蒙替代療法市場的成長。

策略洞察報告細分和範圍：透過檢查以下細分來分析荷爾蒙替代療法市場：治療、應用、給藥途徑和最終用戶。

根據治療方法，荷爾蒙替代療法市場分為雌激素替代療法、生長激素替代療法、甲狀腺激素替代療法、睪固酮替代療法和其他療法。雌激素替代療法在2023年佔據了最大的市場。

荷爾蒙替代療法市場按應用分類，包括更年期、生長激素 (GH) 缺乏症、甲狀腺功能減退症、性腺功能減退症等。更年期療法在 2023 年佔據荷爾蒙替代療法市場的最大佔有率，預計在預測期內將呈現最高的複合年成長率。

區域分析：從區域來看，荷爾蒙替代療法市場報告涵蓋北美、歐洲、亞太地區、南美和中美以及中東和非洲。 2023 年，北美佔據了主導市場佔有率。先進技術的日益普及、荷爾蒙失調盛行率的上升、新產品的早期採用以及主要市場參與者的存在，共同推動了北美荷爾蒙替代療法市場規模的不斷成長。 2023 年 6 月，輝瑞公司和 OPKO Health Inc. 宣布，美國食品藥物管理局 (FDA) 批准了 NGENLA (somatrogon-ghla)，這是一種每週使用一次的人類生長激素類似物，用於治療因內源性生長激素分泌不足導致生長障礙的三歲及以上兒科患者。

此外，在預測期內，對提供優質個人化醫療服務及強化醫療保健解決方案的重視預計將為荷爾蒙替代療法市場創造巨大機會。 2023年5月，首家全國性整合及功能醫學提供者網路Forum Health, LLC收購了德州最大的荷爾蒙替代診所網路之一Hormones by Design。

荷爾蒙替代療法市場報告範圍行業發展和未來機會：正如公司新聞稿所報導的，激素替代療法市場主要參與者的關鍵策略發展包括：

2024年1月，丹麥Ascendis Pharma A/S公司與Vector Pharma FZCO（簡稱Vector）簽署了一項獨家經銷協議，授權其在海灣合作理事會（GCC）國家（包括沙烏地阿拉伯、阿拉伯聯合大公國、科威特、阿曼、卡達和巴林）銷售Yorvipath和Skytrofa。根據該協議，Vector將利用其銷售和市場專長，為GCC國家的患者提供用於治療成人甲狀旁腺功能減退症的Yorvipath和用於治療兒童生長激素缺乏症（GHD）的Skytrofa。競爭格局與重點公司：荷爾蒙替代療法市場報告中介紹的知名公司包括阿斯特捷利康、輝瑞公司、諾華公司、雅培、Tolmar公司、Par Pharmaceutical、Mayne Pharma Group Limited、諾和諾德公司、禮來公司和Noven Pharmaceuticals, Inc.。這些公司專注於開發新技術、改進現有產品並擴大其地理覆蓋範圍，以滿足全球日益成長的消費者需求。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：荷爾蒙替代療法市場格局

  • 概述
  • PEST分析

第5章：荷爾蒙替代療法市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：荷爾蒙替代療法市場－全球市場分析

  • 荷爾蒙替代療法（HRT）-全球市場概覽
  • 荷爾蒙替代療法 (HRT) - 全球市場及 2031 年預測

第7章：荷爾蒙替代療法市場-收入分析-依產品分類，2021-2031

  • 概述
  • 雌激素替代療法
  • 人類生長激素（HGH）替代療法
  • 甲狀腺替代療法
  • 睾酮替代療法
  • 其他

第 8 章：荷爾蒙替代療法市場 - 收入分析 - 按給藥途徑，2021-2031 年

  • 概述
  • 口服
  • 腸外
  • 透皮

第9章：荷爾蒙替代療法市場-收入分析-按疾病適應症，2021-2031

  • 概述
  • 停經
  • 甲狀腺功能低下症
  • 性腺功能低下
  • 生長激素缺乏症
  • 其他

第 10 章：荷爾蒙替代療法市場 - 收入分析 - 按配銷通路，2021-2031 年

  • 概述
  • 醫院
  • 專科診所
  • 其他

第 11 章：荷爾蒙替代療法市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：荷爾蒙替代療法市場 - 主要公司簡介

  • Astrazeneca
  • Pfizer Inc.
  • Novartis AG
  • Abbott
  • Tolmar Inc
  • Par Pharmaceutical
  • Mayne Pharma Group Limited
  • Novo Nordisk A/S
  • Eli Lily And Company
  • Noven Pharmaceuticals, Inc.

第 15 章：附錄

簡介目錄
Product Code: TIPRE00003836

The forecast for the hormone replacement therapy market provides stakeholders with insights to shape their growth strategies. The market is anticipated to expand from US$ 9.85 billion in 2024 to US$ 14.82 billion by 2031, with an estimated CAGR of 7.3% from 2025 to 2031.The global demand for hormone replacement therapy (HRT) is consistently increasing due to factors such as the rising incidence of hormonal disorders, heightened awareness of hormone deficiencies, and advancements in HRT formulations. Bioidentical hormone replacement therapy (BHRT) is gaining popularity over synthetic hormones due to its perceived safety and effectiveness. BHRT, derived from natural sources, is believed to closely mimic the hormones produced by the body.

Pharmaceutical companies are focusing on creating innovative hormone therapy formulations, including transdermal patches, gels, creams, and subcutaneous implants, to enhance patient convenience, adherence, and safety. This trend is driving the growth of the hormone replacement therapy market. In August 2023, the Food and Drug Administration (FDA) approved ANI Pharmaceuticals' abbreviated new drug application for a 0.1% estradiol gel. The reference medication, Divigel, is an estrogen hormone therapy used to alleviate moderate to severe vasomotor symptoms associated with menopause. The generic version of Divigel is estradiol gel, 0.1%.

Growth Drivers:Extensive Applications Fuel Hormone Replacement Therapy Market Growth

Hormone replacement therapy is utilized to alleviate menopause symptoms, treat growth hormone deficiency, and more, significantly impacting individuals' lives. Millions of women utilize HRT, often for extended periods. HRT can help prevent osteoporosis and enhance quality of life in various ways. According to Oregon Health & Science University, growth hormone deficiency (GHD) is relatively rare, affecting about 50,000 adults in the US and approximately one in 4,000 to 6,000 children. Therefore, the increasing adoption of therapy alongside the rising prevalence of hormonal disorders is propelling the growth of the hormone replacement therapy market.

Restraint:High Medication Costs Impede Hormone Replacement Therapy Market Growth

The prices of HRT products are notably high. For example, the monthly cost of oral hormone replacement therapy prescriptions ranges from US$ 130 to US$ 240 (equating to US$ 1,560 to US$ 2,440 annually), as reported by The Menopause Center. These high costs hinder the regular use of these products, thus restraining the growth of the hormone replacement therapy market.

Strategic Insights

Report Segmentation and Scope:The analysis of the hormone replacement therapy market has been conducted by examining the following segments: therapy, application, route of administration, and end user.

By therapy, the hormone replacement therapy market is divided into estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, testosterone replacement, and others. The estrogen hormone replacement segment accounted for the largest market share in 2023.

The hormone replacement therapy market, categorized by application, includes menopause, growth hormone (GH) deficiency, hypothyroidism, hypogonadism, and others. The menopause segment held the largest share of the hormone replacement therapy market in 2023 and is expected to exhibit the highest CAGR during the forecast period.

Regional Analysis:Regionally, the hormone replacement therapy market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America dominated the market share. The increasing adoption of advanced technologies, the rising prevalence of hormonal disorders, early adoption of new products, and the presence of key market players contribute to the growing hormone replacement therapy market size in North America. In June 2023, the US Food and Drug Administration (FDA) approved NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, for treating pediatric patients aged three years and older with growth failure due to insufficient endogenous growth hormone secretion, as announced by Pfizer Inc. and OPKO Health Inc.

Moreover, a heightened focus on providing access to quality personalized care and enhancing healthcare solutions is expected to create significant opportunities for the hormone replacement therapy market during the forecast period. In May 2023, Forum Health, LLC, the first national network of integrative and functional medicine providers, acquired Hormones by Design, one of the largest networks of hormone replacement clinics in Texas.

Hormone Replacement Therapy Market Report Scope

Industry Developments and Future Opportunities:Key strategic developments by leading players in the hormone replacement therapy market, as reported in company press releases, include:

In January 2024, Ascendis Pharma A/S of Denmark and Vector Pharma FZCO (Vector) entered into an exclusive distribution agreement for the commercialization of Yorvipath and Skytrofa in the Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the UAE, Kuwait, Oman, Qatar, and Bahrain. Under this agreement, Vector will leverage its sales and marketing expertise to provide patients in the GCC with Yorvipath for adult hypoparathyroidism and Skytrofa for pediatric growth hormone deficiency (GHD).

Competitive Landscape and Key Companies:Prominent companies profiled in the hormone replacement therapy market report include Astrazeneca, Pfizer Inc., Novartis AG, Abbott, Tolmar Inc., Par Pharmaceutical, Mayne Pharma Group Limited, Novo Nordisk A/S, Eli Lilly and Company, and Noven Pharmaceuticals, Inc. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the increasing consumer demand globally.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hormone Replacement Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Hormone Replacement Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hormone Replacement Therapy Market - Global Market Analysis

  • 6.1 Hormone Replacement Therapy (HRT) - Global Market Overview
  • 6.2 Hormone Replacement Therapy (HRT) - Global Market and Forecast to 2031

7. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Products, 2021-2031

  • 7.1 Overview
  • 7.2 Estrogen Replacement Therapy
  • 7.3 Human Growth Hormone (HGH) Replacement Therapy
  • 7.4 Thyroid Replacement Therapy
  • 7.5 Testosterone Replacement Therapy
  • 7.6 Others

8. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Route Of Administration, 2021-2031

  • 8.1 Overview
  • 8.2 Oral
  • 8.3 Parenteral
  • 8.4 Transdermal

9. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 9.1 Overview
  • 9.2 Menopause
  • 9.3 Hypothyroidism
  • 9.4 Hypogonadism
  • 9.5 Growth Hormone Deficiency
  • 9.6 Others

10. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Others

11. Hormone Replacement Therapy Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Hormone Replacement Therapy Market Overview
    • 11.1.2 North America Hormone Replacement Therapy Market Revenue and Forecasts to 2031
    • 11.1.3 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Products
    • 11.1.4 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Route Of Administration
    • 11.1.5 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Disease Indication
    • 11.1.6 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Hormone Replacement Therapy Market
        • 11.1.7.1.1 United States Hormone Replacement Therapy Market, by Products
        • 11.1.7.1.2 United States Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.1.3 United States Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.1.4 United States Hormone Replacement Therapy Market, by Distribution Channel
      • 11.1.7.2 Canada Hormone Replacement Therapy Market
        • 11.1.7.2.1 Canada Hormone Replacement Therapy Market, by Products
        • 11.1.7.2.2 Canada Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.2.3 Canada Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.2.4 Canada Hormone Replacement Therapy Market, by Distribution Channel
      • 11.1.7.3 Mexico Hormone Replacement Therapy Market
        • 11.1.7.3.1 Mexico Hormone Replacement Therapy Market, by Products
        • 11.1.7.3.2 Mexico Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.3.3 Mexico Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.3.4 Mexico Hormone Replacement Therapy Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Hormone Replacement Therapy Market - Key Company Profiles

  • 14.1 Astrazeneca
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc.
  • 14.3 Novartis AG
  • 14.4 Abbott
  • 14.5 Tolmar Inc
  • 14.6 Par Pharmaceutical
  • 14.7 Mayne Pharma Group Limited
  • 14.8 Novo Nordisk A/S
  • 14.9 Eli Lily And Company
  • 14.10 Noven Pharmaceuticals, Inc.

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud